SHARE

It could be rightly said that Pharmacyte Biotech Inc (OTCMKTS:PMCB) is just making the right moves to establish itself as a long-term player in the healthcare space. After becoming a part of a major research paper, the company noted the appointment of Thomas Liquard as its Board of Directors, who will also become the Chairman of the Audit Committee.

Appointment Of Thomas Liquard

The addition of Liquard into the Board of Directors hold significance for Pharmacyte Biotech Inc (OTCMKTS:PMCB), which is particularly on account of Liquard’s experience track record. Liquard’s extensive hold in the pharmaceutical industry comes from his past work experiences at Alchemia Limited and Pfizer Inc. (NYSE:PFE). Liquard had served Alchemia Ltd as CEO, while he was Senior Director, Portfolio Development Leader Emerging Markets for the Established Products Porfolio at Pfizer in New York. Pharmacyte Biotech Inc (OTCMKTS:PMCB) anticipates to gain tremendously from the past experiences of Liquard at the two pharmaceutical majors.

Mentioned in a research paper

Pharmacyte Biotech Inc (OTCMKTS:PMCB) gained momentum after a research undertaken by Prof. Ann Simpson and her colleagues established that the company’s patented encapsulation technology can reverse Diabetes. The paper titled, “Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen Cells,” threw light on how the company’s unique cell-in-a-Box technology can prevent Melligen cells from being rejected by the body’s immune system. The research concluded that Melligen cells can reverse Type-1 diabetes if Melligen cells are encapsulated before introducing in the human system.

Thus, the research has put the focus back on Pharmacyte Biotech Inc (OTCMKTS:PMCB) by validating its technology and efficiency in treating Diabetes. It is to be noted that the company is also developing treatments for cancer through the same live-cell encapsulation technology. The stock of the company closed 1.16% lower at $0.154 on Tuesday while an average of 2.86 million shares traded on the day.

SHARE
Previous articleWill Propanc Health Group Corp (OTCMKTS:PPCH)’s 8-K filing Be An Eye-Opener For Investors?
Next articleForeverGreen Worldwide Corp (OTCMKTS:FVRG) Is Serious About Its Business
Steve Kanaval
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.